Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging

Nicole Strittmatter, Frances M. Richards, Alan M. Race, Stephanie Ling, Daniel Sutton, Anna Nilsson, Yann Wallez, Jennifer Barnes, Gareth Maglennon, Aarthi Gopinathan, Rebecca Brais, Edmond Wong, Maria Paola Serra, James Atkinson, Aaron Smith, Joanne Wilson, Gregory Hamm, Timothy I. Johnson, Charles R. Dunlop, Brajesh P. KaisthaJosephine Bunch, Owen J. Sansom, Zoltan Takats, Per E. Andrén, Alan Lau, Simon T. Barry, Richard J.A. Goodwin, Duncan I. Jodrell

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Gemcitabine (dFdC) is a common treatment for pancreatic cancer; however, it is thought that treatment may fail because tumor stroma prevents drug distribution to tumor cells. Gemcitabine is a pro-drug with active metabolites generated intracellularly; therefore, visualizing the distribution of parent drug as well as its metabolites is important. A multimodal imaging approach was developed using spatially coregistered mass spectrometry imaging (MSI), imaging mass cytometry (IMC), multiplex immunofluorescence microscopy (mIF), and hematoxylin and eosin (H&E) staining to assess the local distribution and metabolism of gemcitabine in tumors from a genetically engineered mouse model of pancreatic cancer (KPC) allowing for comparisons between effects in the tumor tissue and its microenvironment. Mass spectrometry imaging (MSI) enabled the visualization of the distribution of gemcitabine (100 mg/kg), its phosphorylated metabolites dFdCMP, dFdCDP and dFdCTP, and the inactive metabolite dFdU. Distribution was compared to small-molecule ATR inhibitor AZD6738 (25 mg/kg), which was codosed. Gemcitabine metabolites showed heterogeneous distribution within the tumor, which was different from the parent compound. The highest abundance of dFdCMP, dFdCDP, and dFdCTP correlated with distribution of endogenous AMP, ADP, and ATP in viable tumor cell regions, showing that gemcitabine active metabolites are reaching the tumor cell compartment, while AZD6738 was located to nonviable tumor regions. The method revealed that the generation of active, phosphorylated dFdC metabolites as well as treatment-induced DNA damage primarily correlated with sites of high proliferation in KPC PDAC tumor tissue, rather than sites of high parent drug abundance.

Original languageEnglish
Pages (from-to)1795-1803
Number of pages9
JournalAnalytical Chemistry
Issue number3
StatePublished - 25 Jan 2022


Dive into the research topics of 'Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging'. Together they form a unique fingerprint.

Cite this